Psychiatry and Neurology, Neurology · Wynnewood, PA
NPI
1194723585
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
7
Hospital affiliations
100 E Lancaster Ave, Suite 161
Wynnewood, PA, 19096
Phone (610) 642-5371
Groups this clinician bills Medicare through
Medicare paid, 2024
$452K
49,485 services
Medicare patients, 2024
529
Average age 76
Drug cost, 2024
$1.9M
3,160 prescriptions
Company payments, 2025
$29K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stephen M Gollomp was code J0588 (injection, incobotulinumtoxin a, 1 unit), 36,700 times for 67 patients. In total Stephen M Gollomp billed 49,485 services in 37 codes, and Medicare paid $452K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-02-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 36,700 | 67 | $4.07 | $150K |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 7,601 | 21 | $4.85 | $37K |
| 99497 Care Management/Coordination | Office | 495 | 488 | $61.25 | $30K |
| 99215 Office E&M - Established | Office | 455 | 294 | $143.64 | $65K |
| 99214 Office E&M - Established | Office | 403 | 291 | $86.65 | $35K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 265 | 101 | $50.45 | $13K |
| 95874 Musculoskeletal | Office | 160 | 50 | $63.25 | $10K |
| 95984 Electrical Nerve Conductivity | Office | 151 | 40 | $34.69 | $5,238 |
| 64612 Musculoskeletal | Office | 134 | 40 | $137.40 | $18K |
| 64616 Musculoskeletal | Office | 131 | 37 | $174.20 | $23K |
| 99213 Office E&M - Established | Office | 117 | 37 | $67.45 | $7,892 |
| 95983 Electrical Nerve Conductivity | Office | 109 | 42 | $40.13 | $4,375 |
| 99441 Telephone Services | Office | 92 | 66 | $44.36 | $4,081 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 91 | 63 | $26.72 | $2,432 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 87 | 85 | $13.49 | $1,174 |
By year: 2022 $455K for 49,641 services; 2023 $482K for 52,951 services; 2024 $452K for 49,485 services.
Medicare prescription drug claims, 2024
In 2024, the drug Stephen M Gollomp prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 554 prescriptions and refills. In total Stephen M Gollomp wrote 3,160 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 554 | 1,364 | 153 | $18K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 176 | 414 | 45 | $10K |
| Donepezil Hcl Generic | 162 | 338 | 42 | $2,356 |
| Selegiline Hcl Generic | 128 | 285 | 31 | $14K |
| Clonazepam Generic | 127 | 175 | 25 | $1,091 |
| Gabapentin Generic | 91 | 211 | 25 | $2,256 |
| Propranolol Hcl Er Propranolol Hcl | 90 | 245 | 24 | $4,553 |
| Lorazepam Generic | 74 | 113 | 20 | $740 |
| Propranolol Hcl Generic | 70 | 126 | 22 | $822 |
| Primidone Generic | 62 | 137 | 15 | $1,468 |
| Trihexyphenidyl Hcl Generic | 51 | 115 | 12 | $1,222 |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 49 | 114 | 12 | $17K |
| Ingrezza Valbenazine Tosylate | 45 | 45 | Under 11 | $456K |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 44 | 82 | Under 11 | $1,366 |
| Rasagiline Mesylate Generic | 42 | 118 | 14 | $5,320 |
Brand drugs: - claims; generic drugs: 2,755 claims; opioid claims: 63.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stephen M Gollomp $29K ($29K in general payments such as food, travel and fees) from 25 companies. The largest payer was Neurocrine BioSciences, Inc. with $25K.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 22 | $25K |
| Boston Scientific Corporation BSX | 16 | $1,567 |
| Abbvie Inc. ABBV | 27 | $510 |
| Lilly USA, LLC LLY | 9 | $247 |
| SK Life Science, Inc. | 11 | $217 |
| TG Therapeutics, Inc. TGTX | 3 | $163 |
| Amneal Pharmaceuticals LLC AMRX | 18 | $151 |
| Pfizer Inc. PFE | 11 | $145 |
| Merz Pharmaceuticals, LLC | 3 | $137 |
| Abbott Laboratories ABT | 1 | $97.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.